Kopin Corporation Reports Financial Results for the Fourth Quarter and Full Year 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 Closed $31.0 million. | March 3, 2023
Kala Pharmaceuticals (KALA) Reports Q4, Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million - - Ended 2022 with Cash Balance of $173.7 Million - - Reaffirmed 2023 Financial Guidance - - Conference Call
- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 GAAP Diluted EPS of $(0.09) for the Fourth Quarter of 2.